Phase 2 Atopic Dermatitis trials recruiting now

All Atopic Dermatitis trials, every phase

Other phases for Atopic Dermatitis

Phase 2 Atopic Dermatitis trials

• A Clinical Study to Evaluate SM17 for Atopic Dermatitis
  NCT07445919 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
  NCT07277660 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 68 locations
• A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)
  NCT07355075 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
  NCT07223697 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 29 locations
• A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
  NCT07003425 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 71 locations
• A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in Adult Subjects With Mild to Moderate Atopic Dermatitis
  NCT07598383 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
  NCT07643766 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
  NCT07599813 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 85 locations
• A Phase II Clinical Study Evaluating of ZL-82 Tablets in Atopic Dermatitis
  NCT07193589 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis
  NCT07399067 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
  NCT05995964 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 98 locations
• A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
  NCT06524635 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis
  NCT07330934 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
  NCT07037901 · Phase: Phase 2 · Ages: 18 Years to 74 Years · Sex: All (male and female) · 30 locations
• A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
  NCT07216027 · Phase: Phase 2 · Ages: 18 Years to 64 Years · Sex: All (male and female) · 23 locations
• Cardamom and Topical Roseomonas in Atopic Dermatitis
  NCT06096857 · Phase: Phase 2 · Ages: 2 Years to 100 Years · Sex: All (male and female) · 1 location
• Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
  NCT06397911 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 16 locations
• Evaluate the Efficacy of Using Modified Qing-Ying Decoction in Atopic Dermatitis Children
  NCT04419584 · Phase: Phase 2, Phase 3 · Ages: 4 Years to 17 Years · Sex: All (male and female) · 1 location
• Evaluation of Efficacy and Safety of Oral Roflumilast for Treatment of Moderate to Severe Atopic Dermatitis in Patients Aged 12 Years and Older: A Pilot Study
  NCT07297602 · Phase: Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · 1 location
• HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis
  NCT07629778 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Herbal Ointment in Treating Atopic Dermatitis Topically
  NCT06850311 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• IB/IIa Study of MG-K10 in Adolescent Moderately Severe Patients
  NCT06765005 · Phase: Phase 1, Phase 2 · Ages: 12 Years to 18 Years · Sex: All (male and female) · 1 location
• Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD.
  NCT06855745 · Phase: Phase 2 · Ages: 2 Years and older · Sex: All (male and female) · 12 locations
• Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
  NCT06947993 · Phase: Phase 2 · Ages: 18 Years to 100 Years · Sex: All (male and female) · 105 locations
• Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis
  NCT06947980 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD
  NCT07441395 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome
  NCT07242638 · Phase: Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · 1 location

Common questions

What does Phase 2 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.